151 related articles for article (PubMed ID: 37922880)
1. Synthetic immune checkpoint engagers protect HLA-deficient iPSCs and derivatives from innate immune cell cytotoxicity.
Gravina A; Tediashvili G; Zheng Y; Iwabuchi KA; Peyrot SM; Roodsari SZ; Gargiulo L; Kaneko S; Osawa M; Schrepfer S; Deuse T
Cell Stem Cell; 2023 Nov; 30(11):1538-1548.e4. PubMed ID: 37922880
[TBL] [Abstract][Full Text] [Related]
2. Protection of cell therapeutics from antibody-mediated killing by CD64 overexpression.
Gravina A; Tediashvili G; Rajalingam R; Quandt Z; Deisenroth C; Schrepfer S; Deuse T
Nat Biotechnol; 2023 May; 41(5):717-727. PubMed ID: 36593395
[TBL] [Abstract][Full Text] [Related]
3. Generation of universal natural killer cells from a cryopreserved cord blood mononuclear cell-derived induced pluripotent stem cell library.
Du W; Cui L; Zhang J; Zhang H; Liu R; Yang W; Zhang Y
FEBS Open Bio; 2022 Oct; 12(10):1771-1781. PubMed ID: 35747945
[TBL] [Abstract][Full Text] [Related]
4. iPSC-derived natural killer cells expressing the FcγR fusion CD64/16A can be armed with antibodies for multitumor antigen targeting.
Snyder KM; Dixon KJ; Davis Z; Hosking M; Hart G; Khaw M; Matson A; Bjordahl R; Hancock B; Shirinbak S; Miller JS; Valamehr B; Wu J; Walcheck B
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38056893
[TBL] [Abstract][Full Text] [Related]
5. Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity.
Ellwanger K; Reusch U; Fucek I; Wingert S; Ross T; Müller T; Schniegler-Mattox U; Haneke T; Rajkovic E; Koch J; Treder M; Tesar M
MAbs; 2019 Jul; 11(5):899-918. PubMed ID: 31172847
[TBL] [Abstract][Full Text] [Related]
6. Fit-For-All iPSC-Derived Cell Therapies and Their Evaluation in Humanized Mice With NK Cell Immunity.
Flahou C; Morishima T; Takizawa H; Sugimoto N
Front Immunol; 2021; 12():662360. PubMed ID: 33897711
[TBL] [Abstract][Full Text] [Related]
7. iPSC-derived cells lack immune tolerance to autologous NK-cells due to imbalance in ligands for activating and inhibitory NK-cell receptors.
Bogomiakova ME; Sekretova EK; Anufrieva KS; Khabarova PO; Kazakova AN; Bobrovsky PA; Grigoryeva TV; Eremeev AV; Lebedeva OS; Bogomazova AN; Lagarkova MA
Stem Cell Res Ther; 2023 Apr; 14(1):77. PubMed ID: 37038186
[TBL] [Abstract][Full Text] [Related]
8. NK Cell Alloreactivity against KIR-Ligand-Mismatched HLA-Haploidentical Tissue Derived from HLA Haplotype-Homozygous iPSCs.
Ichise H; Nagano S; Maeda T; Miyazaki M; Miyazaki Y; Kojima H; Yawata N; Yawata M; Tanaka H; Saji H; Masuda K; Kawamoto H
Stem Cell Reports; 2017 Sep; 9(3):853-867. PubMed ID: 28867344
[TBL] [Abstract][Full Text] [Related]
9. NK cells and ILCs in tumor immunotherapy.
Sivori S; Pende D; Quatrini L; Pietra G; Della Chiesa M; Vacca P; Tumino N; Moretta F; Mingari MC; Locatelli F; Moretta L
Mol Aspects Med; 2021 Aug; 80():100870. PubMed ID: 32800530
[TBL] [Abstract][Full Text] [Related]
10. The Impact of HLA Class I-Specific Killer Cell Immunoglobulin-Like Receptors on Antibody-Dependent Natural Killer Cell-Mediated Cytotoxicity and Organ Allograft Rejection.
Rajalingam R
Front Immunol; 2016; 7():585. PubMed ID: 28066408
[TBL] [Abstract][Full Text] [Related]
11. The SIRPα-CD47 immune checkpoint in NK cells.
Deuse T; Hu X; Agbor-Enoh S; Jang MK; Alawi M; Saygi C; Gravina A; Tediashvili G; Nguyen VQ; Liu Y; Valantine H; Lanier LL; Schrepfer S
J Exp Med; 2021 Mar; 218(3):. PubMed ID: 33416832
[TBL] [Abstract][Full Text] [Related]
12. Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation.
Moretta L; Locatelli F; Pende D; Marcenaro E; Mingari MC; Moretta A
Blood; 2011 Jan; 117(3):764-71. PubMed ID: 20889923
[TBL] [Abstract][Full Text] [Related]
13. Generation of individualized immunocompatible endothelial cells from HLA-I-matched human pluripotent stem cells.
Song C; Wang L; Li Q; Liao B; Qiao W; Li Q; Dong N; Li L
Stem Cell Res Ther; 2022 Feb; 13(1):48. PubMed ID: 35109922
[TBL] [Abstract][Full Text] [Related]
14. Targeted Disruption of the β2-Microglobulin Gene Minimizes the Immunogenicity of Human Embryonic Stem Cells.
Wang D; Quan Y; Yan Q; Morales JE; Wetsel RA
Stem Cells Transl Med; 2015 Oct; 4(10):1234-45. PubMed ID: 26285657
[TBL] [Abstract][Full Text] [Related]
15. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells.
Ueda T; Kumagai A; Iriguchi S; Yasui Y; Miyasaka T; Nakagoshi K; Nakane K; Saito K; Takahashi M; Sasaki A; Yoshida S; Takasu N; Seno H; Uemura Y; Tamada K; Nakatsura T; Kaneko S
Cancer Sci; 2020 May; 111(5):1478-1490. PubMed ID: 32133731
[TBL] [Abstract][Full Text] [Related]
16. Enhanced wound healing promotion by immune response-free monkey autologous iPSCs and exosomes vs. their allogeneic counterparts.
Lu M; Peng L; Ming X; Wang X; Cui A; Li Y; Wang X; Meng D; Sun N; Xiang M; Chen S
EBioMedicine; 2019 Apr; 42():443-457. PubMed ID: 30926422
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors.
Wingert S; Reusch U; Knackmuss S; Kluge M; Damrat M; Pahl J; Schniegler-Mattox U; Mueller T; Fucek I; Ellwanger K; Tesar M; Haneke T; Koch J; Treder M; Fischer W; Rajkovic E
MAbs; 2021; 13(1):1950264. PubMed ID: 34325617
[TBL] [Abstract][Full Text] [Related]
18. HLA Class I Knockout Converts Allogeneic Primary NK Cells Into Suitable Effectors for "Off-the-Shelf" Immunotherapy.
Hoerster K; Uhrberg M; Wiek C; Horn PA; Hanenberg H; Heinrichs S
Front Immunol; 2020; 11():586168. PubMed ID: 33584651
[TBL] [Abstract][Full Text] [Related]
19. Anti-TIM3 chimeric antigen receptor-natural killer cells from engineered induced pluripotent stem cells effectively target acute myeloid leukemia cells.
Klaihmon P; Luanpitpong S; Kang X; Issaragrisil S
Cancer Cell Int; 2023 Nov; 23(1):297. PubMed ID: 38012684
[TBL] [Abstract][Full Text] [Related]
20. MHC-matched induced pluripotent stem cells can attenuate cellular and humoral immune responses but are still susceptible to innate immunity in pigs.
Mizukami Y; Abe T; Shibata H; Makimura Y; Fujishiro SH; Yanase K; Hishikawa S; Kobayashi E; Hanazono Y
PLoS One; 2014; 9(6):e98319. PubMed ID: 24927426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
